Business Description
Cipla Ltd
SIC : 2833
ISIN : INE059A01026
Share Class Description:
NSE:CIPLA: Shs DematerialisedTotal Employee Number:
47,496Compare
Compare
Traded in other countries / regions
500087.IndiaCIPLA.Luxembourg Index Membership
NIFTY 50NIFTY 500 IPO Date
1995-02-08Description
Cipla Ltd is an Indian pharmaceutical company that develops, manufactures, and markets generic and branded medicines across a broad range of therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infectives, and central nervous system treatments. Its portfolio spans complex generics, inhalers, biosimilars, and over-the-counter products, sold under brands such as Cipla and Cip-la. The company serves patients, healthcare professionals, hospitals, and governments through its own sales force and distribution partners. India is its largest market, supplemented by significant operations in North America, South Africa, and other emerging and regulated markets. Revenue comes primarily from pharmaceutical product sales, with growing contributions from its consumer healthcare and specialty businesses. Cipla invests in research and development and pursues growth through new product launches, partnerships, and geographic expansion.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.34 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.11 | |||||
Interest Coverage | 71.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 10.72 | |||||
Beneish M-Score | -2.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.2 | |||||
3-Year EBITDA Growth Rate | 7.2 | |||||
3-Year EPS without NRI Growth Rate | 11.5 | |||||
3-Year FCF Growth Rate | -25.2 | |||||
3-Year Book Growth Rate | 13.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.61 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.39 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.81 | |||||
9-Day RSI | 48.48 | |||||
14-Day RSI | 45.81 | |||||
3-1 Month Momentum % | 5.58 | |||||
6-1 Month Momentum % | 12.82 | |||||
12-1 Month Momentum % | -9.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.44 | |||||
Quick Ratio | 2.5 | |||||
Cash Ratio | 1.43 | |||||
Days Inventory | 222.84 | |||||
Days Sales Outstanding | 78.47 | |||||
Days Payable | 110.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.93 | |||||
Dividend Payout Ratio | 0.29 | |||||
3-Year Dividend Growth Rate | 37.5 | |||||
Forward Dividend Yield % | 0.93 | |||||
5-Year Yield-on-Cost % | 0.93 | |||||
Shareholder Yield % | 0.87 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.06 | |||||
Operating Margin % | 14.58 | |||||
Net Margin % | 12.06 | |||||
EBITDA Margin % | 20.95 | |||||
FCF Margin % | 9.02 | |||||
OCF Margin % | 14.67 | |||||
ROE % | 10.26 | |||||
ROA % | 8.42 | |||||
ROIC % | 11.63 | |||||
3-Year ROIIC % | 9.21 | |||||
ROC (Joel Greenblatt) % | 31.49 | |||||
ROCE % | 13.61 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 33.42 | |||||
Forward PE Ratio | 27.38 | |||||
PE Ratio without NRI | 31.19 | |||||
Shiller PE Ratio | 34.53 | |||||
Price-to-Owner-Earnings | 30.56 | |||||
PEG Ratio | 2.81 | |||||
PS Ratio | 4.03 | |||||
PB Ratio | 3.26 | |||||
Price-to-Tangible-Book | 4.06 | |||||
Price-to-Free-Cash-Flow | 130.86 | |||||
Price-to-Operating-Cash-Flow | 28.58 | |||||
EV-to-EBIT | 22.1 | |||||
EV-to-Forward-EBIT | 17.96 | |||||
EV-to-EBITDA | 17.32 | |||||
EV-to-Forward-EBITDA | 15.82 | |||||
EV-to-Revenue | 3.64 | |||||
EV-to-Forward-Revenue | 3.47 | |||||
EV-to-FCF | 117.28 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 1.87 | |||||
Price-to-DCF (Earnings Based) | 1.66 | |||||
Price-to-DCF (FCF Based) | 9.19 | |||||
Price-to-Median-PS-Value | 1.11 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.52 | |||||
Price-to-Graham-Number | 2.21 | |||||
| Price-to-Net-Current-Asset-Value | 6.96 | |||||
| Price-to-Net-Cash | 56.97 | |||||
Earnings Yield (Greenblatt) % | 4.51 | |||||
FCF Yield % | 0.77 | |||||
Forward Rate of Return (Yacktman) % | 13.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Cipla Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 283,244 | ||
| EPS (TTM) (₹) | 41.7 | ||
| Beta | 0.6202 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 21.33 | ||
| 14-Day RSI | 45.81 | ||
| 14-Day ATR (₹) | 23.150766 | ||
| 20-Day SMA (₹) | 1393.905 | ||
| 12-1 Month Momentum % | -9.32 | ||
| 52-Week Range (₹) | 1165.7 - 1673 | ||
| Shares Outstanding (Mil) | 807.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cipla Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cipla Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-01-22 16:00 | In 123 days | ||
| Third quarter earnings results for 2027 | 2027-01-22 | In 122 days | ||
| Second quarter earnings conference call for 2027 | 2026-10-30 16:00 | In 39 days | ||
| Second quarter earnings results for 2027 | 2026-10-30 | In 38 days | ||
| First quarter earnings conference call for 2027 | 2026-07-23 16:00 | 1,415.10 (-0.56%) | ||
| First quarter earnings results for 2027 | 2026-07-23 | 1,415.10 (-0.56%) | ||
| General meeting for 2026 | 2026-06-25 14:00 | 1,437.90 (-0.54%) | ||
| INR 13.000000 Cash Dividend | 2026-06-05 | 1,398.70 (+2.47%) | ||
| Annual report for 2026 | 2026-06-01 | 1,401.00 (-0.71%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-13 16:00 | 1,292.30 (-0.94%) |
Show
Entries
Cipla Ltd Frequently Asked Questions
What is Cipla Ltd(NSE:CIPLA)'s stock price today?
The current price of NSE:CIPLA is ₹1386.10. The 52 week high of NSE:CIPLA is ₹1673.00 and 52 week low is ₹1165.70.
When is next earnings date of Cipla Ltd(NSE:CIPLA)?
The next earnings date of Cipla Ltd(NSE:CIPLA) is 2026-10-30 Est..
Does Cipla Ltd(NSE:CIPLA) pay dividends? If so, how much?
The Dividend Yield % of Cipla Ltd(NSE:CIPLA) is 0.93% (As of Today), Highest Dividend Payout Ratio of Cipla Ltd(NSE:CIPLA) was 0.32. The lowest was 0.1. And the median was 0.16. The Forward Dividend Yield % of Cipla Ltd(NSE:CIPLA) is 0.93%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers